In this issue of Blood, Donato et al report that treatment of venous thromboembolism (VTE) with anticoagulation does not increase the risk of intracranial hemorrhage (ICH) in patients with solid tumors metastatic to the brain. 1 D uring lectures about anticoagulation, an image of a teeter-totter is often presented with bleeding on one side balanced by thrombosis on the other. The patient's age, genetic conditions, medications, and comorbidities stack on either end to influence whether the balance is tipped toward bleeding or clotting. The width of the fulcrum and resulting fluctuation depend upon the clinical scenario. In hospital, mortality of patients with anticoagulation-associated ICH exceeds 30% 2 ; thus, it is rare to find a situation more difficult to balance than anticoagulation in patients with brain metastases. Because of the high risk of hemorrhage, the number of patients with brain lesions enrolled in randomized anticoagulation therapy trials has been limited. The pivotal CLOT trial established superiority of low-molecular-weight heparin over warfarin for VTE treatment in cancer patients; however, only 27 patients with primary brain tumors were included.
3 Less than 1200 cancer patients have been enrolled in trials comparing the direct oral anticoagulants (dabigatran, apixaban, rivaroxaban, and edoxaban) to warfarin. The reports did not include the location of metastatic disease. Cancer patients enrolled in the direct oral anticoagulant trials were highly selected, though, and had a lower risk of recurrent thrombosis compared with patients enrolled in studies of low-molecular-weight heparin. figure) . Significant ICH, defined as a volume .10 mL, neurologic symptoms, or requiring surgical intervention, also did not differ between controls and patients treated with enoxaparin (1-year cumulative incidence of 22% vs 21%, respectively). Patients with renal cell carcinoma or melanoma were at an extraordinarily high risk of ICH (1-year cumulative incidence of 34% for significant bleeds and 58% for all ICH), which did not differ from patients treated with enoxaparin (35% for significant
Cumulative incidence of ICH in patients with metastatic brain tumors. No difference in (A) the cumulative incidence of total and (B) significant ICH (.10 mL, symptomatic, or necessitating neurosurgery) was found in cancer patients with brain metastases when the control group (blue) was compared with patients treated with enoxaparin (red). See Figure 1B -C in the article by Donato et al that begins on page 494.
ICH and 55% for all ICH). Improvements in imaging and significantly longer follow-up could explain the higher incidence of ICH in this study. Conflict-of-interest disclosure: The author declares no competing financial interests. n Platelet secretion paves the way
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In this issue of Blood, Sakurai et al 1 examine the response of single platelets to fibrinogen-and collagen-coated microdots and show that platelets can orient their release of a-granule cargo to promote spreading beyond the dot's boundary.
A dvances in imaging and microfabrication are increasing our ability to observe individual platelets and thus are expanding our views of what platelets can do and how they do it. Increases in imaging resolution (ie, super-resolution microscopy and total internal reflection microscopy), acquisition speeds, and computational techniques coupled with the production of microscale surfaces and fluidics systems are revolutionizing how we dissect platelet function on the micro-and molecular scales. The work of Sakurai et al 1 is one such example of how imaging and microprinting technologies are expanding our understanding of how platelets sense and modify their local microenvironments.
Sakurai and colleagues use microprinting to generate surfaces on which platelets are allowed to spread. Their overall goal is to determine how the biophysical properties of a matrix affect a platelet's response. Previous work by the Lam group showed that matrix stiffness increased platelet adhesion and spreading as well as a IIb b 3 activation, and both P-selectin and phosphatidylserine exposure. The authors also noticed that platelets, when bound to defined, microcontact-printed surfaces (coated with fibrinogen), dynamically extended filopodia in all directions, apparently sampling their microenvironment. Platelets could extend filopodia across uncoated regions of up to 5 mm in width.
3 This previous work demonstrated the platelet's ability to sense and to respond to the spatial constraints of their local microenvironment. In their present work, Sakurai et al create fibrinogen-and collagen-coated microdots of different diameters to assess how geometric orientation of the matrix and spatial sensing affect platelet exocytosis and spreading. The surface covered by individual platelets increased as the dot's diameter, reaching a maximum on dots of 7 mm (38.5 mm 2 ).
Surprisingly, the area covered by platelets decreased slightly as the microdot diameters increased. Closer examination of the platelets, spread on the smaller dots, showed that they were extending beyond the microdot edges onto the unprinted surfaces. Further imaging analysis showed that there was a concentration of P-selectin at the edges of the smaller microdots, which was not seen as platelets spread on the larger (.7 mm) microdots. Platelets spreading on micropatterns containing uncoated holes also showed a concentration of P-selectin at the coated/uncoated boundaries. Indeed, it appeared that secretion of some granule cargo (ie, fibrinogen, fibronectin, and P-selectin) was directed to these boundary regions and thus was depositing matrix for further platelet extension beyond the boundary. Activated a IIb b 3 was concentrated in these boundary regions, but GP1b was
